Brucellosis (Malta Fever)

1. Overview

Brucellosis is a systemic zoonotic infection caused by Brucella species, small Gram-negative, facultatively intracellular coccobacilli. It represents one of the most common zoonotic diseases worldwide, with an estimated 500,000 new human cases annually, though true incidence is likely 10-25 times higher due to underreporting and misdiagnosis. [1,2]

The disease is endemic in the Mediterranean Basin, Middle East, Central Asia, Latin America, and Sub-Saharan Africa, with case fatality rates of less than 2% when treated appropriately, but reaching 20-80% mortality in cases complicated by endocarditis. [3,4] The hallmark clinical features are undulant (wavelike) fever, profuse night sweats classically described as having a "mouldy" or "hay-like" odour, and hepatosplenomegaly. Brucellosis is known as "the great mimicker" due to its protean manifestations affecting virtually every organ system. [5]

Transmission occurs primarily through consumption of unpasteurised dairy products (particularly soft cheeses and raw milk) or direct occupational contact with infected animals and their products. The organisms possess remarkable intracellular survival mechanisms, residing within macrophages and evading host immune responses, which explains the requirement for prolonged combination antibiotic therapy (minimum 6 weeks) and the significant risk of relapse with inadequate treatment. [6,7]

Key Clinical Messages

Think Brucellosis: Travel to endemic regions + unpasteurised dairy consumption + fever with hepatosplenomegaly = high suspicion
Hold Blood Cultures: Brucella is slow-growing; cultures must be held for 21 days or processed in automated systems
Never Monotherapy: Relapse rates exceed 30% with single-agent therapy; always use combination regimens
Screen for Complications: Actively exclude spondylodiscitis, endocarditis, and neurobrucellosis in all cases
Laboratory Hazard: Brucella is one of the most common causes of laboratory-acquired infection; notify laboratory when suspected

2. Epidemiology

Global Burden

Brucellosis remains a major public health concern globally, particularly in resource-limited settings where surveillance is suboptimal. The World Health Organization estimates 500,000 new cases annually, but systematic reviews suggest this represents only 4-10% of actual cases due to widespread underdiagnosis. [1,2]

Epidemiological Parameter	Value	Evidence Source
Global annual incidence (reported)	500,000 cases	WHO estimates [1]
True estimated incidence	5-12.5 million cases	Systematic review extrapolation [2]
Endemic region prevalence	1-200 per 100,000	Regional surveillance data [8]
Case fatality rate (treated)	less than 1-2%	Meta-analysis [3]
Case fatality rate (endocarditis)	20-80%	Case series [4]
Relapse rate (combination therapy)	5-15%	Treatment meta-analysis [9]
Relapse rate (monotherapy)	> 30%	Historical data [10]

Geographic Distribution

Region	Endemicity	Predominant Species	Notes
Mediterranean Basin	High	B. melitensis	Greece, Spain, Italy, Turkey, North Africa
Middle East	Very High	B. melitensis	Saudi Arabia, Iran, Iraq, Syria, Jordan
Central Asia	High	B. melitensis, B. abortus	Kazakhstan, Kyrgyzstan, Tajikistan
Latin America	Moderate-High	B. melitensis, B. suis	Mexico, Peru, Argentina
Sub-Saharan Africa	High (underreported)	B. melitensis, B. abortus	Limited surveillance data
India/South Asia	Moderate	B. melitensis, B. abortus	Urban and rural populations
Western Europe/USA	Low	Imported cases	Rare; travel-associated, imported food
UK	Very Low	Imported only	less than 50 cases/year; travel and occupational

Brucella Species and Reservoir Hosts

Four species account for nearly all human disease, with significant variation in virulence and clinical manifestations. [5,11]

Species	Primary Host	Human Virulence	Clinical Severity	Geographic Association
B. melitensis	Goats, Sheep	Highest	Most severe disease; highest complication rate	Mediterranean, Middle East
B. abortus	Cattle	Moderate	Generally milder; still causes focal complications	Worldwide (declining with eradication)
B. suis	Pigs (wild boar, feral swine)	Moderate-High	Variable; associated with suppurative lesions	Americas, Southeast Asia
B. canis	Dogs	Low	Often subclinical; rare human disease	Sporadic worldwide
B. ceti / B. pinnipedialis	Marine mammals	Rare	Occupational in marine workers	Coastal regions
B. inopinata	Unknown	Very Rare	Few case reports	Unknown

Transmission Routes

Route	Mechanism	Risk Groups	Relative Frequency
Ingestion	Unpasteurised milk, soft cheeses (queso fresco, feta), ice cream, raw meat	Travellers, consumers of traditional foods	Most common (60-70%)
Direct Contact	Handling infected animals, aborted foetuses, placentas, birthing products	Farmers, shepherds, veterinarians, abattoir workers	Occupational (20-30%)
Inhalation	Aerosols during animal slaughter, laboratory manipulation, contaminated dust	Laboratory workers, abattoir workers, farmers	Significant in occupational settings
Conjunctival	Splash exposure to contaminated fluids	Veterinarians, laboratory workers	Rare but documented
Transplacental	Vertical transmission in pregnancy	Pregnant women with active infection	Rare; causes foetal loss
Sexual	Sexual transmission (controversial)	Partners of infected individuals	Very rare; case reports only
Blood Transfusion/Transplant	Blood products, organ transplantation	Recipients in endemic areas	Extremely rare

Risk Factors for Human Infection

Risk Factor	Mechanism	Relative Risk
Unpasteurised dairy consumption	Direct ingestion of organisms	High
Occupational animal contact	Direct and aerosol exposure	High
Travel to endemic regions	Dietary and environmental exposure	Moderate-High
Laboratory work with Brucella	Aerosol hazard during culture	High (without precautions)
Male sex	More occupational exposure	2-3:1 male predominance
Age 20-60 years	Working age, occupational exposure	Peak incidence
Immunocompromise	Reduced clearance	Prolonged/severe disease

3. Microbiology and Pathophysiology

Bacteriology

Brucella species are small (0.5-0.7 × 0.6-1.5 μm), Gram-negative coccobacilli with distinctive microbiological characteristics essential for understanding their pathogenicity and laboratory detection. [5,6]

Characteristic	Description	Clinical Relevance
Morphology	Gram-negative coccobacilli, non-motile, non-spore-forming	Often mistaken for other small GNRs
Growth	Aerobic, CO₂-dependent (especially primary isolation), slow-growing	Requires prolonged incubation (21 days)
Culture Media	Blood agar, Brucella agar, BACTEC systems	Alert laboratory for prolonged hold
Colony Morphology	Small, smooth, honey-coloured colonies after 48-72 hours	Smooth (S) → virulent; Rough (R) → attenuated
Biochemistry	Oxidase +, Catalase +, Urease + (variable), H₂S production (variable)	Species differentiation
Intracellular Pathogen	Facultatively intracellular; survives within macrophages	Explains treatment duration requirements

Virulence Factors

Virulence Factor	Mechanism	Pathogenic Consequence
Smooth Lipopolysaccharide (S-LPS)	Contains O-polysaccharide chain; major surface antigen	Evades complement; stimulates antibody response (basis of serology)
Type IV Secretion System (VirB)	Injects effector proteins into host cells	Essential for intracellular survival and replication
BvrR/BvrS Two-Component System	Regulates gene expression for cell invasion	Modulates virulence gene expression
Cyclic β-1,2-Glucan	Intracellular osmoregulation	Prevents phagosome-lysosome fusion
Outer Membrane Proteins (Omp25, Omp31)	Cell surface adhesins	Facilitate cell entry and immune evasion
Erythritol Preference	Utilises erythritol (abundant in ungulate placenta)	Explains tropism for reproductive tissues; causes abortion in animals

Pathogenesis: Molecular Mechanisms

The pathogenesis of brucellosis involves a sophisticated interplay between bacterial virulence mechanisms and host immune evasion, resulting in the characteristic chronic, relapsing nature of the disease. [6,12]

Entry and Initial Infection

Mucosal penetration: Organisms enter via intestinal mucosa (ingestion), respiratory epithelium (inhalation), or skin abrasions (direct contact)
M-cell transcytosis: In intestine, Brucella exploits M cells to cross mucosal barrier
Initial phagocytosis: Captured by resident macrophages and dendritic cells

Intracellular Survival Strategy

Phagosome modification: Following phagocytosis, Brucella-containing vacuole (BCV) undergoes unique maturation
Avoidance of lysosomal fusion: Type IV secretion system delivers effector proteins that prevent phagosome-lysosome fusion
ER-derived replicative niche: BCV acquires ER markers and becomes the replicative Brucella-containing vacuole (rBCV)
Intracellular replication: Organisms multiply to high numbers within modified compartment
Cell-to-cell spread: Infected macrophages traffic bacteria to reticuloendothelial organs

Immune Evasion Mechanisms

Mechanism	Effect	Clinical Consequence
S-LPS low immunogenicity	Reduced TLR4 activation compared to enterobacterial LPS	Blunted innate immune response
Type IV secretion effectors	Inhibit dendritic cell maturation	Impaired adaptive immunity
Intracellular location	Protection from antibodies and complement	Explains relapse despite antibodies
Macrophage reprogramming	Shift from M1 (pro-inflammatory) to M2 (anti-inflammatory)	Chronic infection establishment
Granuloma formation	Contains but does not eradicate infection	Latency with potential reactivation

Dissemination and Organ Tropism

Following initial replication at entry sites, bacteraemia develops with haematogenous and lymphatic dissemination to the reticuloendothelial system (RES):

Target Organ	Pathological Features	Clinical Manifestation
Liver	Granulomatous hepatitis, hepatomegaly	Elevated LFTs, hepatomegaly
Spleen	Granulomas, splenomegaly, occasionally abscess	Splenomegaly, left upper quadrant pain
Bone Marrow	Granulomas, hypoplasia, haemophagocytosis	Pancytopenia, bone marrow failure
Lymph Nodes	Reactive hyperplasia, granulomas	Lymphadenopathy
Skeletal System	Sacroiliitis, spondylodiscitis, osteomyelitis, arthritis	Back pain, joint pain, limited mobility
Genitourinary	Epididymo-orchitis, oophoritis, prostatitis	Scrotal pain, pelvic pain
Cardiovascular	Endocarditis (valvular vegetations)	Murmur, heart failure, emboli
CNS	Meningitis, encephalitis, myelitis, abscess	Headache, confusion, focal deficits

Immunology

The host immune response to Brucella involves both innate and adaptive components, with successful clearance requiring robust Th1-type cell-mediated immunity. [6,13]

Immune Component	Role in Brucellosis	Clinical Significance
Macrophages	Initial phagocytosis; paradoxically serve as replicative niche	Ineffective killing allows persistence
Neutrophils	Limited role; Brucella resists neutrophil killing	Not protective
NK Cells	Early IFN-γ production	Contributes to granuloma formation
CD4+ Th1 Cells	IFN-γ, TNF-α production; macrophage activation	Critical for protective immunity
CD8+ T Cells	Cytotoxic killing of infected cells	Important for resolution
Antibodies	Useful diagnostically; limited protective role	Serology aids diagnosis but not protection
Granulomas	Non-caseating granulomas contain infection	Balance between control and tissue damage

Why Combination Therapy is Essential

The intracellular niche of Brucella has profound therapeutic implications:

Antibiotic penetration: Only certain antibiotics achieve adequate intracellular concentrations
Prolonged therapy: Slow bacterial replication and dormancy require extended treatment
Synergy requirement: Combination therapy prevents resistance and enhances killing
Relapse risk: Monotherapy failure rates exceed 30% due to incomplete eradication

Effective Antibiotic	Intracellular Activity	Mechanism
Doxycycline	Excellent	Concentrates in acidic vacuolar environment
Rifampicin	Excellent	Lipophilic; penetrates macrophages
Aminoglycosides	Good (in combination)	Enhanced by doxycycline-induced vacuolar changes
Fluoroquinolones	Good	Intracellular accumulation
Trimethoprim-Sulfamethoxazole	Moderate-Good	Reasonable CNS penetration

4. Clinical Presentation

Incubation Period

The incubation period is typically 1-4 weeks but can range from 5 days to several months, with longer incubation associated with lower inoculum exposure. [5,14]

Clinical Forms

Form	Timing	Clinical Features	Prognosis
Acute	less than 8 weeks from onset	High fever, sweats, acute systemic illness	Good with treatment
Subacute	8-52 weeks	Fluctuating symptoms, focal complications emerging	Requires prolonged therapy
Chronic	> 52 weeks	Persistent fatigue, depression, low-grade fever, controversy over entity	Often refractory
Localised/Focal	Any time	Predominant organ involvement (skeletal, neural, cardiac)	Depends on site
Relapse	Typically 3-6 months post-treatment	Recurrence of symptoms; rising titres	Requires retreatment

Cardinal Symptoms

Symptom	Frequency	Clinical Characteristics
Fever	80-100%	Undulant (wavelike) pattern with evening spikes; may be continuous initially
Night Sweats	40-90%	Drenching; classically "mouldy" or "hay-like" odour
Malaise/Fatigue	80-95%	Profound; often debilitating; persists into convalescence
Arthralgia/Myalgia	40-70%	Migratory; affects large joints; may precede focal arthritis
Headache	40-60%	May indicate neurobrucellosis if severe/persistent
Anorexia	40-60%	Weight loss in prolonged cases
Back Pain	20-50%	RED FLAG: suggests sacroiliitis or spondylodiscitis
Testicular Pain	5-10% (males)	Epididymo-orchitis
Abdominal Pain	15-25%	Hepatosplenomegaly, mesenteric lymphadenopathy

Physical Examination Findings

Sign	Frequency	Clinical Significance
Fever	80-100%	Document pattern (undulant vs continuous)
Hepatomegaly	30-70%	Moderate enlargement; may be tender
Splenomegaly	20-60%	Can be massive in chronic cases
Lymphadenopathy	10-30%	Cervical and axillary most common
Arthritis	10-40%	Monoarticular or oligoarticular; knee, hip, sacroiliac
Spinal Tenderness	10-30%	Lumbar > thoracic; suggests spondylodiscitis
Epididymo-Orchitis	5-10%	Unilateral swelling; mimics tumour
Cardiac Murmur	less than 2%	RED FLAG: suggests endocarditis
Neurological Signs	less than 5%	Meningism, cranial nerve palsies, focal deficits

System-Specific Manifestations

Musculoskeletal (30-80%)

The musculoskeletal system is the most common site of focal brucellosis, with sacroiliitis and spondylodiscitis being particularly characteristic. [15,16]

Manifestation	Frequency	Features	Prognosis
Sacroiliitis	10-30%	Unilateral > bilateral; FABER test positive; buttock/thigh pain	Good with treatment
Spondylodiscitis	5-15%	Lumbar > thoracic > cervical; disc space narrowing on imaging	Prolonged therapy required
Peripheral Arthritis	10-40%	Knee > hip > ankle; usually oligoarticular	Resolves with antibiotics
Osteomyelitis	less than 5%	Vertebral or long bone involvement	May require surgery
Bursitis/Tenosynovitis	Rare	Various sites	Responds to treatment

Genitourinary (2-20%)

Manifestation	Sex	Features	Notes
Epididymo-Orchitis	Male	Unilateral swelling, pain; mimics testicular tumour	5-10% of male cases; may form abscess
Prostatitis	Male	Dysuria, pelvic pain	Less common
Ovarian Abscess	Female	Pelvic mass, fever	Rare
Spontaneous Abortion	Pregnant	First/second trimester loss	Risk varies by species; B. melitensis highest
Glomerulonephritis	Either	Immune complex-mediated	Rare

Neurobrucellosis (2-10%)

Neurobrucellosis carries significant morbidity and requires specialised management. [17]

Manifestation	Features	Diagnosis	Treatment
Meningitis	Chronic lymphocytic; headache, neck stiffness, fever	CSF: lymphocytic pleocytosis, high protein, low glucose; PCR/culture	CNS-penetrating regimen
Meningoencephalitis	Confusion, cognitive changes, seizures	Imaging + CSF analysis	Extended therapy
Cranial Neuropathy	VIII > VI > VII involvement; hearing loss, diplopia	Clinical + audiometry	May be permanent
Myelitis	Paraparesis, sensory level, sphincter dysfunction	MRI spine	Variable recovery
Brain Abscess	Focal deficits, raised ICP	MRI brain	Surgical drainage may be needed
Peripheral Neuropathy	Radiculopathy, mononeuritis multiplex	EMG/NCS	Usually reversible

Cardiovascular (less than 2%)

Brucellar endocarditis is rare but accounts for the majority of brucellosis-related deaths. [4,18]

Feature	Detail
Frequency	less than 2% of cases
Valve Affected	Aortic > Mitral; often previously abnormal valves
Presentation	New murmur, heart failure, embolic phenomena, stroke
Diagnosis	Echocardiography (vegetations); blood culture
Mortality	20-80% even with treatment
Management	Prolonged triple antibiotics + valve surgery often required

Haematological

Manifestation	Frequency	Mechanism	Significance
Anaemia	30-60%	Bone marrow involvement, chronic disease	Usually normocytic
Leukopenia	20-40%	Bone marrow suppression, hypersplenism	Typical finding
Thrombocytopenia	10-30%	Same as above	Usually mild-moderate
Pancytopenia	5-15%	Severe bone marrow involvement	Indicates severe disease
HLH	Rare	Macrophage activation syndrome	Life-threatening

Hepatic

Manifestation	Frequency	Features
Granulomatous Hepatitis	30-50%	Elevated ALP > transaminases; hepatomegaly
Hepatic Abscess	Rare	Fever, RUQ pain, imaging findings

Presentation in Special Populations

Pregnancy

Consideration	Detail
Risk	Spontaneous abortion, intrauterine death, preterm delivery
Transmission	Transplacental; neonatal infection possible
Treatment	Rifampicin + TMP-SMX (avoid doxycycline, aminoglycosides)
Outcome	Good foetal outcome if treated promptly

Paediatric

Consideration	Detail
Presentation	Often non-specific; fever, arthralgia, hepatosplenomegaly
Complications	Similar to adults but lower endocarditis rate
Treatment	TMP-SMX + rifampicin (avoid doxycycline less than 8 years)

Immunocompromised

Consideration	Detail
Course	More severe, prolonged bacteraemia
Complications	Higher rate of focal disease
Treatment	Standard regimens; consider longer duration

5. Diagnosis

Clinical Suspicion Criteria

Brucellosis should be suspected in any patient with:

Fever of unknown origin + hepatosplenomegaly
Travel to or residence in endemic area
Consumption of unpasteurised dairy products
Occupational exposure (farmers, veterinarians, abattoir workers, laboratory personnel)
Undulant fever pattern with drenching night sweats
Fever + sacroiliitis or spondylodiscitis

Laboratory Diagnosis

Culture (Gold Standard)

Method	Specimen	Yield	Considerations
Blood Culture	Blood	15-70%	Hold for 21 days; BACTEC can detect in 7 days
Bone Marrow Culture	Aspirate	70-90%	Higher yield than blood; consider if blood negative
Tissue Culture	Lymph node, liver, abscess	Variable	Submit if biopsy performed
CSF Culture	CSF	10-30%	Low sensitivity; PCR preferred
Joint Fluid Culture	Synovial fluid	Variable	In septic arthritis cases

CRITICAL: Notify the laboratory when brucellosis is suspected to:

Ensure prolonged incubation
Implement Biosafety Level 3 precautions
Prevent laboratory-acquired infection

Serology

Test	Method	Interpretation	Limitations
Standard Agglutination Test (SAT/Wright)	Tube agglutination	≥1:160 diagnostic (endemic); ≥1:80 (non-endemic + symptoms)	Prozone phenomenon; cross-reactions
Rose Bengal Test (RBT)	Rapid card agglutination	Screening test; positive warrants SAT	Lower specificity
Coombs Test (Anti-human Globulin)	Detects blocking antibodies	For chronic/relapse cases when SAT negative	More sensitive for chronic disease
ELISA (IgM, IgG, IgA)	Enzyme immunoassay	IgM: acute; IgG: past or chronic; rising titres diagnostic	More sensitive and specific than SAT
Brucellacapt	Immunocapture agglutination	Detects blocking antibodies	Useful in chronic cases
2-Mercaptoethanol (2-ME) Test	Inactivates IgM	Detects IgG; indicates active infection	Helps distinguish acute from past

Serological Interpretation Pearls:

SAT titres ≥1:160 are diagnostic in appropriate clinical context
Rising titres (≥4-fold) confirm acute infection
Titres may remain elevated for years after cure; single titre not reliable for monitoring
Prozone phenomenon: High antibody titres cause false negatives; request dilutions
B. canis does not react with standard SAT antigens (rough LPS); requires specific testing

Molecular Diagnosis (PCR)

Method	Specimen	Sensitivity	Advantages
Real-time PCR	Blood, tissue, CSF	80-95%	Rapid; not affected by antibiotics
Multiplex PCR	Various	Variable	Species identification
Genus-specific PCR	Various	High	Good for culture-negative cases

PCR is particularly valuable in:

Culture-negative cases
Patients already on antibiotics
Neurobrucellosis (CSF)
Monitoring treatment response (experimental)

Supportive Investigations

Investigation	Expected Findings	Notes
FBC	Anaemia, leukopenia, thrombocytopenia (pancytopenia in severe)	Non-specific but suggestive
LFTs	Elevated ALP, mild transaminase elevation	Granulomatous hepatitis
CRP/ESR	Elevated	Non-specific inflammatory markers
Blood Film	Reactive changes; rarely organism visible	Usually unhelpful
Bone Marrow	Granulomas, haemophagocytosis if HLH	Consider if pancytopenia

Imaging

Modality	Indication	Findings
MRI Spine	Suspected spondylodiscitis	Disc space narrowing, endplate erosion, paravertebral abscess, epidural extension
MRI Sacroiliac Joints	Suspected sacroiliitis	Bone marrow oedema, erosions, joint fluid
Echocardiography	Suspected endocarditis	Vegetations, valvular regurgitation, abscess
CT Abdomen	Hepatosplenomegaly, abscess	Organomegaly, focal lesions
MRI Brain	Neurobrucellosis	Meningeal enhancement, granulomas, abscess, white matter changes

Lumbar Puncture (if neurobrucellosis suspected)

Parameter	Typical Findings
Opening Pressure	Normal or elevated
WCC	Lymphocytic pleocytosis (10-500 cells/μL)
Protein	Elevated (0.5-2 g/L)
Glucose	Low (CSF:plasma ratio less than 0.5)
Culture	Positive in 10-30%
PCR	More sensitive than culture
Antibodies	CSF SAT or ELISA

Diagnostic Criteria Summary

Confirmed Case:

Clinically compatible illness AND
Laboratory confirmation: Culture positive OR ≥4-fold rise in antibody titre OR single titre ≥1:160 with compatible symptoms

Probable Case:

Clinically compatible illness AND
Epidemiological link AND
Single elevated titre (≥1:160 endemic; ≥1:80 non-endemic)

6. Differential Diagnosis

Condition	Key Distinguishing Features	Diagnostic Tests
Typhoid Fever	Rose spots, relative bradycardia, constipation then diarrhoea, travel to South Asia	Blood culture, Widal test
Tuberculosis	Pulmonary symptoms, chronic course, positive contacts, caseating granulomas	CXR, sputum AFB, IGRA/Mantoux
Q Fever	Similar occupational exposure, pneumonia common, hepatitis	Coxiella serology (Phase I and II)
Infective Endocarditis	Murmur, embolic phenomena, classic organisms (Strep, Staph)	Blood cultures, echo
Malaria	Travel to endemic area, cyclical rigors, splenomegaly	Thick/thin film, RDT
Leptospirosis	Water exposure, conjunctival suffusion, AKI, jaundice	Leptospira serology, PCR
Visceral Leishmaniasis	Massive splenomegaly, pancytopenia, travel to endemic area	Bone marrow aspirate, serology
Lymphoma	B symptoms, lymphadenopathy, night sweats	Lymph node biopsy, imaging
HIV Seroconversion	Risk factors, generalised lymphadenopathy, rash	HIV serology
Reactive Arthritis	Recent diarrhoea/STI, HLA-B27 associated, asymmetric oligoarthritis	Clinical diagnosis
Ankylosing Spondylitis	Chronic inflammatory back pain, HLA-B27, bilateral sacroiliitis	MRI sacroiliac joints, HLA-B27

7. Management

Principles of Treatment

Combination therapy essential: Monotherapy relapse rates exceed 30%
Prolonged duration: Minimum 6 weeks for uncomplicated; longer for focal disease
Intracellular activity: Select antibiotics that penetrate macrophages
Monitor for complications: Active surveillance for spondylodiscitis, endocarditis, neurobrucellosis
Follow-up: Clinical and serological monitoring post-treatment

First-Line Treatment Regimens

Regimen	Drugs	Duration	Evidence Level	Notes
WHO Standard (Oral)	Doxycycline 100mg BD + Rifampicin 600-900mg OD	6 weeks	Level I	Convenient; slightly higher relapse than aminoglycoside
Preferred (Injectable)	Doxycycline 100mg BD + Streptomycin 1g IM OD	6 weeks doxy + 2-3 weeks strep	Level I	Lower relapse rate; aminoglycoside inconvenient
Alternative (Injectable)	Doxycycline 100mg BD + Gentamicin 5mg/kg IV OD	6 weeks doxy + 1-2 weeks gent	Level II	Alternative to streptomycin

Meta-analysis evidence [9,10]:

Doxycycline + aminoglycoside: Relapse rate 3-5%
Doxycycline + rifampicin: Relapse rate 8-15%
Aminoglycoside-containing regimens preferred for severe disease

Treatment of Complicated/Focal Disease

Complication	Regimen	Duration	Additional Measures
Spondylodiscitis	Doxycycline + Rifampicin ± Aminoglycoside	3-6 months	MRI monitoring; surgery if instability/abscess
Neurobrucellosis	Doxycycline + Rifampicin + TMP-SMX (or Ceftriaxone)	3-6 months	CNS-penetrating agents essential
Endocarditis	Doxycycline + Rifampicin + Aminoglycoside	≥3-6 months	Valve surgery often required
Epididymo-Orchitis	Standard regimen	6 weeks	Usually responds well
Hepatic Abscess	Standard regimen	6 weeks	Drainage if large

Special Populations

Population	Recommended Regimen	Considerations
Pregnancy	Rifampicin 600mg OD + TMP-SMX (until term)	Avoid doxycycline, aminoglycosides
Children less than 8 years	TMP-SMX + Rifampicin	Avoid doxycycline (teeth staining)
Children ≥8 years	As adult regimen (weight-adjusted)	Doxycycline safe
Renal Impairment	Adjust aminoglycoside dose	Monitor levels; avoid prolonged use
Hepatic Impairment	Consider TMP-SMX instead of rifampicin	Rifampicin hepatotoxic

Alternative Agents

Drug	Role	Notes
Fluoroquinolones	Alternative for doxycycline intolerance	Ciprofloxacin, Ofloxacin; good intracellular activity
TMP-SMX	Component of some regimens	Good CNS penetration
Ceftriaxone	Neurobrucellosis adjunct	CNS penetration
Tigecycline	Severe/resistant cases	Limited experience

Rifampicin Drug Interactions

Rifampicin is a potent CYP450 inducer with numerous clinically significant interactions. [19]

Drug Class	Example	Interaction	Management
Oral Contraceptives	Combined OCP	Reduced efficacy	Use barrier contraception
Anticoagulants	Warfarin	Reduced INR	Increase warfarin dose; monitor closely
HIV Antiretrovirals	PIs, NNRTIs	Reduced ARV levels	Use rifabutin; consult HIV specialist
Antidiabetics	Sulfonylureas	Reduced effect	Increase dose; monitor glucose
Corticosteroids	Prednisolone	Reduced effect	May need higher doses
Statins	Atorvastatin	Reduced effect	Monitor lipids
Immunosuppressants	Ciclosporin, Tacrolimus	Reduced levels	Therapeutic drug monitoring
Antifungals	Fluconazole, Itraconazole	Reduced levels	Consider alternatives
Antiepileptics	Phenytoin, Carbamazepine	Complex interactions	Monitor levels

Monitoring During Treatment

Parameter	Frequency	Purpose
Clinical assessment	Weekly initially, then fortnightly	Response to treatment, adverse effects
LFTs	Baseline, 2 weeks, 4 weeks	Rifampicin hepatotoxicity
FBC	Baseline, then as indicated	Bone marrow recovery
Renal function	If aminoglycosides used	Nephrotoxicity monitoring
Aminoglycoside levels	If prolonged aminoglycoside	Ototoxicity, nephrotoxicity prevention

Follow-Up Protocol

Timepoint	Assessment	Notes
End of treatment	Clinical resolution; consider serology	SAT may remain elevated
3 months post-treatment	Clinical review; serology	Watch for relapse
6 months post-treatment	Final review	Confirm cure
12 months	If complicated disease	Long-term follow-up

Indicators of Relapse

Feature	Notes
Timing	Usually within 3-6 months of treatment completion
Symptoms	Return of fever, sweats, arthralgia
Serology	Rising titres on serial testing
Culture	May become positive again
Risk factors	Short treatment, monotherapy, poor adherence, focal disease

Treatment Outcomes

Outcome	Rate	Notes
Cure (combination therapy)	85-95%	Higher with aminoglycoside regimen
Relapse (combination therapy)	5-15%	Higher with rifampicin-only regimen
Mortality (uncomplicated)	less than 1-2%	Excellent with treatment
Mortality (endocarditis)	20-80%	Major cause of death

8. Complications

Frequency and Severity

Complication	Frequency	Severity	Mortality	Treatment Duration
Sacroiliitis	10-30%	Moderate	Low	3-6 months
Spondylodiscitis	5-15%	Moderate-Severe	Low	3-6 months
Peripheral Arthritis	10-40%	Mild-Moderate	Very Low	6 weeks
Epididymo-Orchitis	5-10% (males)	Moderate	Very Low	6 weeks
Neurobrucellosis	2-10%	Severe	5-10%	3-6 months
Endocarditis	less than 2%	Life-Threatening	20-80%	≥6 months + surgery
Hepatic Abscess	Rare	Moderate	Low	6 weeks + drainage
Pancytopenia	5-15%	Moderate-Severe	Low	Resolves with treatment
HLH	Rare	Life-Threatening	High	Immunomodulation
Chronic Brucellosis	5-10%	Chronic	Very Low	Controversial

Spondylodiscitis: Detailed Management

Feature	Detail
Most common site	Lumbar spine (50-70%) > Thoracic > Cervical
Imaging	MRI: Disc space narrowing, endplate erosions, Romanus lesions, paravertebral abscess
Key differentials	TB spondylitis (Pott's disease), Pyogenic osteomyelitis
Treatment	Doxycycline + Rifampicin ± Aminoglycoside for 3-6 months
Surgical indications	Spinal instability, neurological compromise, abscess requiring drainage
Outcome	Good with prolonged antibiotics; residual back pain common

Endocarditis: Detailed Management

Feature	Detail
Risk factors	Pre-existing valve disease, prosthetic valves
Valve involvement	Aortic > Mitral > Tricuspid
Presentation	Fever, new murmur, heart failure, embolic events (stroke, splenic infarcts)
Diagnosis	Echocardiography (TTE/TEE); blood culture
Medical therapy	Triple therapy: Doxycycline + Rifampicin + Aminoglycoside for ≥3-6 months
Surgical therapy	Often required (40-80% cases); valve replacement
Mortality	20-80% even with optimal treatment
Key message	Low threshold for surgery; medical therapy alone frequently insufficient

Neurobrucellosis: Detailed Management

Feature	Detail
Presentations	Meningitis, meningoencephalitis, brain abscess, myelitis, cranial neuropathy
Diagnosis	CSF analysis: lymphocytic pleocytosis, high protein, low glucose; CSF antibodies; PCR
Treatment	CNS-penetrating regimen: Doxycycline + Rifampicin + TMP-SMX (or Ceftriaxone) for 3-6 months
Outcome	Variable; hearing loss and cranial neuropathies may be permanent
Monitoring	Serial lumbar punctures to confirm CSF normalisation

Chronic Brucellosis

Aspect	Detail
Definition	Persistent symptoms > 12 months despite treatment
Symptoms	Fatigue, depression, diffuse pain, low-grade fever
Controversy	Debate whether represents persistent infection or post-infectious syndrome
Serology	Often persistently positive (may not indicate active infection)
Culture	Usually negative
Management	Supportive; psychological support; further antibiotics rarely beneficial

9. Prognosis and Outcomes

Overall Prognosis

Parameter	Value	Notes
Mortality (treated, uncomplicated)	less than 1-2%	Excellent prognosis
Mortality (untreated)	2-5%	Higher in pre-antibiotic era
Mortality (endocarditis)	20-80%	Major cause of death
Cure rate	85-95%	With appropriate combination therapy
Relapse rate	5-15%	Higher with rifampicin-only regimen
Chronic symptoms	5-10%	Fatigue, depression, chronic pain

Prognostic Factors

Factor	Impact on Prognosis
Species	B. melitensis = worst outcomes
Delay in diagnosis	Longer delay = higher complication rate
Focal complications	Endocarditis = high mortality; spondylodiscitis = prolonged therapy
Age	Extremes of age = worse outcomes
Treatment adherence	Non-adherence = higher relapse rate
Immunocompromise	More severe, prolonged disease
Duration of therapy	less than 6 weeks = high relapse
Regimen	Monotherapy = > 30% relapse

Long-Term Sequelae

Sequela	Frequency	Notes
Chronic fatigue	5-10%	May persist months to years
Chronic back pain	Variable	After spondylodiscitis
Hearing loss	Rare	Neurobrucellosis with VIII nerve involvement
Neurological deficits	Rare	After neurobrucellosis
Valve dysfunction	After endocarditis	May require long-term follow-up

10. Prevention

Public Health Measures

Measure	Target	Effectiveness
Dairy pasteurisation	General population	Highly effective; cornerstone of prevention
Animal vaccination	Livestock (cattle, sheep, goats)	Reduces animal prevalence and human risk
Test and slaughter	Infected herds	Elimination programmes successful in many countries
Surveillance	Disease reporting	Enables outbreak detection
Education	Farmers, travellers, consumers	Awareness of transmission routes

Animal Vaccination Programmes

Vaccine	Species	Target Animal	Notes
S19	B. abortus	Cattle	Live attenuated; causes abortion if given to pregnant cattle
RB51	B. abortus	Cattle	Rough mutant; safer in pregnant cattle
Rev1	B. melitensis	Sheep, Goats	Live attenuated; highly effective
B. suis vaccines	B. suis	Pigs	Less widely used

Occupational Protection

Occupation	Prevention Measures
Farmers/Shepherds	Gloves for handling placentas/abortuses; hand hygiene; avoid contact with birthing fluids
Veterinarians	PPE; care with live vaccines (human infection risk); needle stick prevention
Abattoir Workers	PPE; respiratory protection; wound care
Laboratory Workers	BSL-3 precautions; biosafety cabinets; alert for clinical suspicion
Dairy Workers	Pasteurisation protocols; hygiene

Laboratory Safety

Aspect	Requirement
Biosafety Level	BSL-3 required for culture manipulation
Notification	Alert laboratory when Brucella suspected BEFORE sending samples
Post-Exposure Prophylaxis	Consider Doxycycline + Rifampicin for 3 weeks after unprotected exposure
Surveillance	Monitor exposed personnel for 6 months

Travel Advice

For travellers to endemic regions (Mediterranean, Middle East, Central/South America):

Avoid unpasteurised milk, cheese, and ice cream
Choose pasteurised or UHT dairy products
Beware local soft cheeses in markets (queso fresco, feta, fresh mozzarella)
If unwell after travel with fever, sweats, joint pain — inform doctor of travel history and dietary exposures

Human Vaccine Development

Currently, no licensed human vaccine exists for brucellosis. Research continues into:

Subunit vaccines
Live attenuated strains
DNA vaccines
Recombinant vector vaccines

11. Key Guidelines and Evidence Summary

Major Guidelines

Organisation	Guideline	Key Recommendations
WHO	Brucellosis in Humans and Animals	Global standard; doxycycline + rifampicin or aminoglycoside for 6 weeks
CDC	Brucellosis Reference Guide	US perspective; emphasis on laboratory safety
ESCMID	Management of Brucellosis	European guidance; evidence-based treatment algorithms

Landmark Evidence

Study	Finding	Impact
Solera et al., 1995	Doxycycline + streptomycin superior to doxycycline + rifampicin	Aminoglycoside regimen preferred
Skalsky et al., 2008 (Cochrane) [9]	Meta-analysis confirming aminoglycoside-containing regimens have lower relapse	Evidence-based treatment selection
Yousefi-Nooraie et al., 2012 [10]	Systematic review of treatment regimens	Confirmed 6-week minimum duration
Ariza et al., 2007	Comprehensive clinical review	Standard reference for clinical management

Evidence Levels for Key Recommendations

Recommendation	Evidence Level	Source
Combination therapy mandatory	Level I	Multiple RCTs, meta-analyses [9,10]
6-week minimum duration	Level I	RCTs [9]
Aminoglycoside regimen has lower relapse	Level I	Meta-analysis [9]
Extended therapy for focal disease	Level II-III	Case series, expert consensus
Surgery for endocarditis	Level III	Case series [4,18]

12. Exam-Focused Content

High-Yield Facts for MRCP/FRACP

Fact	Exam Relevance
B. melitensis from goats/sheep is most virulent	Species identification
Blood cultures held for 21 days	Laboratory practice
SAT ≥1:160 diagnostic in endemic areas	Serological interpretation
Doxycycline + Streptomycin has lowest relapse rate	Treatment selection
Endocarditis is main cause of death	Complication awareness
Spondylodiscitis most common focal complication	Pattern recognition
BSL-3 required for laboratory handling	Infection control

Common Exam Scenarios

Scenario 1: Travel-Related Fever

Stem: 45-year-old returns from Turkey with 3 weeks of undulant fever, drenching sweats, and hepatosplenomegaly. Ate local unpasteurised cheese.
Diagnosis: Brucellosis
Investigation: Blood culture (hold 21 days), Brucella serology (SAT, ELISA)
Treatment: Doxycycline 100mg BD + Rifampicin 600mg OD for 6 weeks

Scenario 2: Occupational Exposure

Stem: Veterinarian develops fever, back pain, and positive FABER test. Works with sheep during lambing season.
Diagnosis: Brucellosis with sacroiliitis
Investigation: MRI sacroiliac joints, Brucella serology, blood culture
Treatment: Doxycycline + Rifampicin ± Aminoglycoside for 3-6 months

Scenario 3: Neurobrucellosis

Stem: Patient with known brucellosis develops severe headache, neck stiffness, and hearing loss.
Diagnosis: Neurobrucellosis (meningitis with VIII nerve involvement)
Investigation: Lumbar puncture (lymphocytic pleocytosis, low glucose), CSF Brucella antibodies/PCR
Treatment: Doxycycline + Rifampicin + TMP-SMX for 3-6 months

Scenario 4: Endocarditis

Stem: Patient with brucellosis develops new aortic regurgitation murmur and splenic infarct.
Diagnosis: Brucellar endocarditis
Investigation: Echocardiography (vegetations), blood cultures
Treatment: Triple therapy (Doxycycline + Rifampicin + Aminoglycoside) + valve surgery

Scenario 5: Laboratory Exposure

Stem: Microbiology technician develops fever after handling culture later identified as Brucella.
Action: Notify occupational health; consider post-exposure prophylaxis (Doxycycline + Rifampicin for 3 weeks); monitor for 6 months

Viva Questions and Model Answers

Q: What are the Brucella species and their reservoir hosts?

A: "The four main Brucella species causing human disease are:

B. melitensis from goats and sheep — the most virulent, causing the most severe human disease
B. abortus from cattle — moderately virulent
B. suis from pigs — intermediate virulence
B. canis from dogs — least virulent, rare human disease

B. melitensis is responsible for the majority of human cases worldwide, particularly in the Mediterranean and Middle East."

Q: Why is combination therapy essential in brucellosis?

A: "Brucella is a facultatively intracellular pathogen that survives and replicates within macrophages by inhibiting phagosome-lysosome fusion. This intracellular location has several therapeutic implications:

Only antibiotics with good intracellular penetration are effective
Monotherapy results in relapse rates exceeding 30%
Combination therapy provides synergistic killing and prevents resistance
Prolonged treatment (minimum 6 weeks) is required due to slow bacterial replication

The preferred regimen is doxycycline plus an aminoglycoside, which has the lowest relapse rate of approximately 5%."

Q: How do you diagnose neurobrucellosis?

A: "Neurobrucellosis is diagnosed through:

Clinical features: chronic meningitis, encephalitis, cranial neuropathies (especially VIII nerve), or myelitis
CSF analysis: lymphocytic pleocytosis, elevated protein, low glucose (similar to TB meningitis)
CSF Brucella antibodies: positive agglutination test or ELISA in CSF
CSF PCR: more sensitive than culture
Neuroimaging: MRI may show meningeal enhancement, granulomas, or white matter changes
Response to treatment: clinical improvement with appropriate antibiotics

Treatment requires CNS-penetrating agents for 3-6 months: doxycycline plus rifampicin plus either TMP-SMX or ceftriaxone."

Q: A patient with brucellosis develops a new murmur. What are your concerns and management?

A: "This is extremely concerning for brucellar endocarditis, which is the main cause of mortality in brucellosis with fatality rates of 20-80%.

My management would be:

Immediate echocardiography — TTE initially, TEE if TTE inconclusive
Blood cultures — typically positive
Assess for embolic complications — stroke, splenic infarcts, mycotic aneurysms
Cardiothoracic surgery consultation — valve surgery is required in the majority of cases

Medical treatment is triple therapy: doxycycline plus rifampicin plus an aminoglycoside for at least 3-6 months. However, medical therapy alone is frequently insufficient, and early surgical intervention improves outcomes."

Common Mistakes (What Fails Candidates)

Mistake	Consequence	Correct Approach
Not requesting prolonged blood culture incubation	Missed diagnosis	Request 21-day hold; alert laboratory
Prescribing monotherapy	High relapse rate	Always combination therapy
Stopping treatment at 6 weeks for spondylodiscitis	Relapse	3-6 months for focal disease
Missing endocarditis	Mortality	Low threshold for echocardiography
Forgetting rifampicin interactions	Drug failures	Review all medications; counsel patients
Not notifying laboratory	Lab-acquired infection	Always alert before sending samples

13. Quality Audit Standards

Standard	Target	Notes
Blood cultures held ≥21 days when Brucella suspected	100%	Laboratory protocol
Combination antibiotic therapy prescribed	100%	No monotherapy
Treatment duration ≥6 weeks for uncomplicated	100%	Evidence-based
Treatment duration ≥3 months for focal disease	100%	Spondylodiscitis, neurobrucellosis
Echocardiography performed if murmur/embolic signs	100%	Endocarditis screening
Laboratory notified of suspected Brucella	100%	Biosafety
Follow-up at 3 months post-treatment	> 90%	Relapse detection
Rifampicin drug interactions reviewed	100%	Patient safety

14. Patient Information

What is Brucellosis?

Brucellosis is a bacterial infection that you can catch from animals, particularly by eating unpasteurised dairy products (like certain cheeses and raw milk) or through direct contact with infected farm animals. It is common in some parts of the world, including the Mediterranean, Middle East, and Latin America.

What are the Symptoms?

Fever that comes and goes (undulant fever)
Drenching night sweats (sometimes described as having an unusual smell)
Tiredness and weakness
Muscle and joint aches
Loss of appetite and weight loss
Back pain (may indicate a more serious complication)

How is it Diagnosed?

Your doctor will perform blood tests to look for the bacteria or antibodies your body makes against it. Blood cultures need to be kept for longer than usual (up to 3 weeks) because the bacteria grow slowly.

How is it Treated?

Brucellosis is treated with a combination of two antibiotics for at least 6 weeks. It is essential to complete the full course — stopping early can cause the infection to return. Common antibiotics used include doxycycline and rifampicin.

Key Points for Patients

Complete your antibiotics: The full 6-week course is essential to prevent relapse
Attend follow-up appointments: We need to check that the infection has cleared
Avoid unpasteurised dairy in future: This is how most people catch brucellosis
Tell us about drug interactions: Rifampicin interacts with many medications including contraceptive pills
Report new symptoms: Especially back pain, headache, or heart symptoms

Patient FAQs

Question	Answer
"How did I catch this?"	Most likely from unpasteurised dairy products or contact with infected animals
"Can I spread it to my family?"	Person-to-person spread is extremely rare. Your family is safe
"Why such a long course of antibiotics?"	The bacteria hide inside your cells, so it takes longer to eliminate them
"I feel better — can I stop early?"	No. Stopping early causes relapse in many cases. Complete the full course
"Will I fully recover?"	Yes. With proper treatment, the vast majority make a full recovery
"Can I catch it again?"	Yes, if you consume unpasteurised dairy again. Avoid this in future

15. Historical Context

Discovery and Naming

1887: Sir David Bruce, a British military physician, isolated the causative organism from the spleens of soldiers who died of "Malta Fever" on the island of Malta. The genus Brucella is named in his honour.
1897: M. Louis Hughes coined the term "undulant fever" to describe the characteristic wavelike fever pattern.
1905: Themistocles Zammit, a Maltese physician, discovered that goats were the reservoir and unpasteurised goat's milk the vehicle of transmission.
1918: Alice Evans, an American microbiologist, demonstrated that B. abortus (from cattle) could also cause human disease, providing the scientific basis for milk pasteurisation advocacy.
1920s onwards: Pasteurisation programmes in developed countries dramatically reduced human brucellosis incidence.

Impact of Eradication Programmes

Successful bovine brucellosis eradication through test-and-slaughter and vaccination programmes has made human disease rare in:

United Kingdom
United States
Canada
Australia
Northern and Western Europe

Endemic disease persists in regions where animal control programmes are incomplete or where pasteurisation is not universal.

16. References

Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis. 2006;6(2):91-99. doi:10.1016/S1473-3099(06)70382-6
Dean AS, Crump L, Greter H, Schelling E, Zinsstag J. Global burden of human brucellosis: a systematic review of disease frequency. PLoS Negl Trop Dis. 2012;6(10):e1865. doi:10.1371/journal.pntd.0001865
Franco MP, Mulder M, Gilman RH, Smits HL. Human brucellosis. Lancet Infect Dis. 2007;7(12):775-786. doi:10.1016/S1473-3099(07)70286-4
Reguera JM, Alarcón A, Miralles F, Pachón J, Juárez C, Colmenero JD. Brucella endocarditis: clinical, diagnostic, and therapeutic approach. Eur J Clin Microbiol Infect Dis. 2003;22(11):647-650. doi:10.1007/s10096-003-1026-z
Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med. 2005;352(22):2325-2336. doi:10.1056/NEJMra050570
Martirosyan A, Moreno E, Gorvel JP. An evolutionary strategy for a stealthy intracellular Brucella pathogen. Immunol Rev. 2011;240(1):211-234. doi:10.1111/j.1600-065X.2010.00982.x
Ariza J, Bosilkovski M, Cascio A, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med. 2007;4(12):e317. doi:10.1371/journal.pmed.0040317
Rubach MP, Halliday JE, Cleaveland S, Crump JA. Brucellosis in low-income and middle-income countries. Curr Opin Infect Dis. 2013;26(5):404-412. doi:10.1097/QCO.0b013e3283638104
Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ. 2008;336(7646):701-704. doi:10.1136/bmj.39497.500903.25
Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev. 2012;10:CD007179. doi:10.1002/14651858.CD007179.pub2
Whatmore AM, Koylass MS, Muchowski J, Edwards-Smallbone J, Sherwin LR, Mayfield CI. Extended multilocus sequence analysis to describe the global population structure of the genus Brucella: phylogeography and relationship to biovars. Front Microbiol. 2016;7:2049. doi:10.3389/fmicb.2016.02049
de Figueiredo P, Ficht TA, Rice-Ficht A, Rossetti CA, Adams LG. Pathogenesis and immunobiology of brucellosis: review of Brucella-host interactions. Am J Pathol. 2015;185(6):1505-1517. doi:10.1016/j.ajpath.2015.03.003
Baldwin CL, Goenka R. Host immune responses to the intracellular bacteria Brucella: does the bacteria instruct the host to facilitate chronic infection? Crit Rev Immunol. 2006;26(5):407-442. doi:10.1615/critrevimmunol.v26.i5.30
Bosilkovski M, Krteva L, Dimzova M, Kondova I. Brucellosis in 418 patients from the Balkan Peninsula: exposure-related differences in clinical manifestations, laboratory test results, and therapy outcome. Int J Infect Dis. 2007;11(4):342-347. doi:10.1016/j.ijid.2006.10.002
Bosilkovski M, Dimzova M, Grozdanovski K. Natural history of brucellosis in an endemic area. Croat Med J. 2009;50(5):457-464. doi:10.3325/cmj.2009.50.457
Colmenero JD, Ruiz-Mesa JD, Plata A, et al. Clinical findings, therapeutic approach, and outcome of brucellar vertebral osteomyelitis. Clin Infect Dis. 2008;46(3):426-433. doi:10.1086/525266
Guven T, Ugurlu K, Ergonul O, et al. Neurobrucellosis: clinical and diagnostic features. Clin Infect Dis. 2013;56(10):1407-1412. doi:10.1093/cid/cit072
Keshtkar-Jahromi M, Razavi SM, Gholamin S, et al. Medical versus medical and surgical treatment for brucella endocarditis. Ann Thorac Surg. 2012;94(6):2141-2146. doi:10.1016/j.athoracsur.2012.07.006
Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42(9):819-850. doi:10.2165/00003088-200342090-00003
Seleem MN, Boyle SM, Sriranganathan N. Brucellosis: a re-emerging zoonosis. Vet Microbiol. 2010;140(3-4):392-398. doi:10.1016/j.vetmic.2009.06.021

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. It does not replace professional medical advice. If you have symptoms of brucellosis, please seek medical attention.

Clinical board

Urgent signals

Exam focus

Linked comparisons

Editorial and exam context